Inovio and Partner Advance MERS Vaccine

An article from FierceVaccines
October 21, 2015
Inovio Affiliate GeneOne Files Investigational New Drug Application
No vaccine exists for MERS virus, which has killed 40% of those infected
PLYMOUTH MEETING, Pa., Oct. 19, 2015 (GLOBE NEWSWIRE) -- GeneOne Life Science Inc. (KSE:011000), which partnered with Inovio Pharmaceuticals, Inc. (NASDAQ: INO) to develop Inovio's MERS vaccine (GLS-5300), today announced the filing of an Investigational New Drug Application (IND) for GLS-5300 with the United States Food and Drug Administration. The companies expect to move the MERS vaccine into a phase I clinical trial in healthy volunteers before year end.
Middle East respiratory syndrome (MERS) is caused by a coronavirus that is related to the severe acute respiratory syndrome (SARS) virus that over 10 years ago infected over 8,000 people, with a 10% death rate. There is no vaccine or effective treatment against MERS, which spreads from human to human. Since 2012, MERS has infected over 1,500 people and killed almost 600 (40%). Recently, the largest outbreak outside of Saudi Arabia of this emergent global health concern infected 186 people with 36 fatalities in South Korea.
Read the full article here.
Common Disease Taxonomy: